RLX 030(serelaxin)analysis in Acute Heart Failure
Results from a new analysis of the Phase III RELAX-AHF study published in the European Heart Journal and presented as a late breaker at the European Society of Cardiology (ESC) congress in Amsterdam indicate that the investigational medicine RLX 030 from Novartis, consistently improved symptoms and mortality across multiple subgroups of patients with Acute Heart Failure (AHF) assessed in the trial.
The addition of RLX 030 to conventional treatment led to improvements in breathlessness (dyspnoea) and mortality at 6 months across all pre-specified subgroups including those with renal impairment (eGFR<50ml min), the elderly ( more than="75" years) and patients with atrial fibrillation, although the small numbers of patients in each group limit the statistical conclusions that can be drawn.>
Results from RELAX-AHF previously presented in 2012 demonstrated that RLX 030 reduced the risk of death by more than one-third (37%) compared with conventional treatment at six months. RLX030 is currently the only drug for which a reduction in all-cause mortality has been observed in patients with AHF in a major study.
see Metra et al. Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX- AHF. Eur Heart J 2013 Sept 2; ePub ahead of print (doi: 10.1093/eurheartj/eht371.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins